‘Time to Load Up,’ Says KeyBanc About UnitedHealth Stock

UnitedHealth shares have declined roughly 40% year-to-date due to underwhelming results, a CEO transition, suspended guidance, rising costs, and a DOJ investigation, driving its P/E valuation to a decade low. KeyBanc's Matthew Gillmor believes the stock has overshot to the downside and assigns an Outperform rating, citing a historically discounted valuation and potential for earnings recovery in 2026 through corrective actions in Medicare Advantage bids and coding accuracy. Gillmor's revised price target of $400 still offers a one-year upside of 31%.

Analysis

UnitedHealth (UNH) shares have experienced a significant downturn, declining approximately 40% year-to-date, which has pushed its price-to-earnings (P/E) ratio to its lowest level in over a decade. This underperformance stems from a confluence of factors including disappointing Q1 results, an unexpected CEO transition, the suspension of financial guidance, rising Medicare Advantage (MA) costs, under-coding issues with new Optum enrollees for 2024, and a Department of Justice investigation into potential Medicare fraud. Despite these challenges, KeyBanc analyst Matthew Gillmor posits that the stock's decline is excessive, with its forward P/E multiple contracting to around 12x compared to its historical range of 17-19x. Gillmor's analysis suggests the market is pricing in overly pessimistic scenarios, such as near 0% margins for the MA segment. He projects a normalized long-term multiple of 14x, implying an EPS power of approximately $21.50, which is $8.25 per share below UnitedHealth's original 2025 guidance. Corrective actions, such as more conservative MA bids and improved coding accuracy via the HouseCalls program, are anticipated to address these issues by 2026. Gillmor estimates that even partial success, like recovering $1.5 billion in Optum revenue and a 1% improvement in MA margins, could add roughly $2.50 to EPS. Consequently, Gillmor maintains an Outperform rating, with a revised price target of $400, indicating a potential 31% upside. The broader Wall Street consensus is a Moderate Buy, with an average price target of $378.32, implying a 24% premium. The overall sentiment from the article signals a moderately positive outlook, driven by the analyst's belief in a recovery.

Key Decisions for Investors

• Investors might consider the current historically discounted valuation of UNH as a potential entry point, particularly if they have a long-term horizon and can tolerate near-term volatility given the analyst's view that the stock has overshot to the downside.
• Monitor closely UnitedHealth's execution on proposed corrective measures, specifically the June Medicare Advantage bids and improvements in Optum's coding accuracy, as these are critical catalysts for the anticipated earnings recovery in 2026.
• Factor in the elevated uncertainty stemming from the ongoing Department of Justice investigation and the inherent risks associated with the successful implementation of turnaround strategies, despite the analyst's optimistic price target.